Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALISADE-4: Fasedienol Nasal Spray for Social Anxiety Disorder
NCT06615557Phase 3Completed
- Sponsor
- Vistagen Therapeutics
- Start
- Sep 2024
- Primary completion
- Apr 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Social Anxiety Disorder (SAD) comparing Fasedienol Nasal Spray with Placebo Nasal Spray (2 arms). Primary endpoint: Subjective Units of Distress Scale at 7 days. Started Sep 2024; status: completed.
02
Drugs
fasedienol
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT06615557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06615557.